Zobrazeno 1 - 8
of 8
pro vyhledávání: '"59"'
Autor:
Carl G. Figdor, Judith P. Johnson, Ursula Günthert, Barbara Mayer, Friedrich W. Schildberg, K. W. Jauch, Ilona Funke
Publikováno v:
The Lancet. 342:1019-1022
We have examined the cell surface molecule CD44, which is attracting interest because of reports that isoforms are associated with metastasis. The prognostic value of CD44 expression has yet to be assessed for a solid tumour. Benign (59) and malignan
Autor:
Mohamedraed Elshami, Abdallah Alwali, Khamis Elessi, Mahmoud Hamouda, Alaa Al-aqad, Saad Al massri, Mohammad Alswerki
Publikováno v:
The Lancet. 398:S11
Background Poor control of cancer pain is a major public health problem worldwide. Many potential barriers can lead to suboptimal treatment of cancer pain. One such barrier is inadequate measurement and assessment of cancer-related pain control. This
Autor:
J.G.M. Klijn, Caroline Seynaeve, Peter Devilee, A.N. van Geel, L. Dukel, C.T.M. Brekelmans, L.C. Verhoog, Amw van den Ouweland, Mma Tilanus-Linthorst, E.J. Meijers-Heijboer, Anja Wagner
Publikováno v:
Lancet, 355(9220), 2015-2020. Elsevier Limited
Lancet (UK), 355, 2015-2020. Elsevier Ltd.
Lancet (UK), 355, 2015-2020. Elsevier Ltd.
Germline mutations in the BRCA1 and BRCA2 genes highly predispose to breast and ovarian cancer. In families with BRCA1 or BRCA2 mutations, identification of mutation carriers is clinically relevant in view of the options for surveillance and preventi
Autor:
Masashi Goto, Takeshi Iwanaga, Toshifusa Nakajima, Tsuyoshi Kito, Kenzo Okabayashi, Michiro Sasaki, Atsushi Nashimoto, Masatsugu Kitamura
Publikováno v:
The Lancet. 354:273-277
Summary Background To study the survival benefit of adjuvant chemotherapy in gastric cancer, seven cancer centres in Japan carried out a phase III clinical trial of adjuvant chemotherapy after curative gastrectomy for macroscopically serosa-negative
Autor:
Grace L. Lu-Yao, Siu-Long Yao
Publikováno v:
The Lancet. 349:906-910
Summary Background Choice of treatment in localised prostate cancer has been hampered by a lack of unbiased, representative data on outcome. Most existing data have come from small cohorts at specialised academic centres; precise overall and cancer-g
Publikováno v:
The Lancet. 343:1122-1126
In Japan the standard adjuvant treatment after resection of gastric cancer is intravenous mitomycin plus oral fluorouracil. We have assessed the efficacy of protein-bound polysaccharide (PSK) in addition to standard chemotherapy in patients who had u
Autor:
Lone Susanne Jensen, Frank Viborg Mortensen, Erzsébet Puhó, Lars Pedersen, Henrik Toft Sørensen
Publikováno v:
Jensen, L S, Puho, E, Pedersen, L, Mortensen, F V & Sørensen, H T 2005, ' Long-term survival after colorectal surgery associated with buffy-coat-poor and leucocyte-depleted blood transfusion. A follow-up study. ', Lancet, vol. 365, no. 9460, pp. 681-682 .
Summary A Danish clinical trial showed that transfusion with leucocyte-depleted red blood cells reduces postoperative infectious complications compared with cells without buffy-coat. However, the effect on long-term outcome is unknown. We followed up
Autor:
Kirk M. Chan-Tack
Publikováno v:
The Lancet. 359:823
29 Shivapurkar N, Wiethege T, Wistuba II, Milchgrub S, Muller KM, Gazdar AF. Presence of simian virus 40 sequences in malignant pleural, peritoneal and noninvasive mesotheliomas. Int J Cancer 2000; 85: 743–45. 30 Waheed I, Guo ZS, Chen GA, Weiser T